{"id":"anti-mrsa-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This drug works by inhibiting the enzyme responsible for cell wall synthesis in MRSA bacteria, ultimately leading to bacterial cell death. This mechanism of action is specific to bacterial cell wall synthesis and is not effective against other types of bacteria or viruses.","oneSentence":"Targets bacterial cell wall synthesis to inhibit MRSA growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:07.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of complicated urinary tract infections caused by MRSA"}]},"trialDetails":[{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT07376889","phase":"PHASE4","title":"Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2026-02-01","conditions":"Staphylococcus Aureus Bacteremia","enrollment":2096},{"nctId":"NCT06238297","phase":"NA","title":"Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia","status":"RECRUITING","sponsor":"University of Bari Aldo Moro","startDate":"2024-05-06","conditions":"Pneumonia, Bacterial","enrollment":76},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":"Methicillin-susceptible S. Aureus (MSSA), Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA), Complicated Skin and Soft Tissue,cSSTI","enrollment":144},{"nctId":"NCT06827496","phase":"","title":"Initial Oral Antibiotics for Bone and Joint Infections in Children","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Osteomyelitis Acute, Septic Arthritis, Bone Infection","enrollment":100},{"nctId":"NCT06096012","phase":"","title":"Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2023-06-23","conditions":"Osteomyelitis","enrollment":365},{"nctId":"NCT03506113","phase":"PHASE4","title":"GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial","status":"COMPLETED","sponsor":"Osaka General Medical Center","startDate":"2018-04-01","conditions":"Ventilator Associated Pneumonia","enrollment":206},{"nctId":"NCT02547116","phase":"PHASE4","title":"Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2020-12","conditions":"Cystic Fibrosis, MRSA","enrollment":""},{"nctId":"NCT01984684","phase":"PHASE3","title":"Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-05","conditions":"Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections","enrollment":850},{"nctId":"NCT01811732","phase":"PHASE3","title":"Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2013-04","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":660},{"nctId":"NCT02218359","phase":"PHASE2","title":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization","status":"WITHDRAWN","sponsor":"Cardeas Pharma","startDate":"2014-10","conditions":"Pneumonia, Bacterial","enrollment":""},{"nctId":"NCT02443064","phase":"PHASE4","title":"Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2014-01","conditions":"Blood Stream Infections, Endocarditis, MRSA","enrollment":100},{"nctId":"NCT00676130","phase":"NA","title":"Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2007-05","conditions":"Cellulitis","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anti-MRSA Antibiotics"],"phase":"phase_2","status":"active","brandName":"Anti-MRSA therapy","genericName":"Anti-MRSA therapy","companyName":"Methodist Health System","companyId":"methodist-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Targets bacterial cell wall synthesis to inhibit MRSA growth. Used for Treatment of complicated urinary tract infections caused by MRSA.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}